Multi-center real-world comparison of the fully automated Idylla™ microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer.
Velasco A., Tokat F., Bonde J., Trim N., Bauer E., Meeney A., de Leng W., Chong G., Dalstein V., Kis LL., Lorentzen JA., Tomić S., Thwaites K., Putzová M., Birnbaum A., Qazi R., Primmer V., Dockhorn-Dworniczak B., Hernández-Losa J., Soares FA., Gertler AA., Kalman M., Wong C., Carraro DM., Sousa AC., Reis RM., Fox SB., Fassan M., Brevet M., Merkelbach-Bruse S., Colling R., Soilleux E., Teo RYW., D'Haene N., Nolet S., Ristimäki A., Väisänen T., Chapusot C., Soruri A., Unger T., Wecgowiec J., Biscuola M., Frattini M., Long A., Campregher PV., Matias-Guiu X.
Microsatellite instability (MSI) is present in 15-20% of primary colorectal cancers. MSI status is assessed to detect Lynch syndrome, guide adjuvant chemotherapy, determine prognosis, and use as a companion test for checkpoint blockade inhibitors. Traditionally, MSI status is determined by immunohistochemistry or molecular methods. The Idylla™ MSI Assay is a fully automated molecular method (including automated result interpretation), using seven novel MSI biomarkers (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, SULF2) and not requiring matched normal tissue. In this real-world global study, 44 clinical centers performed Idylla™ testing on a total of 1301 archived colorectal cancer formalin-fixed, paraffin-embedded (FFPE) tissue sections and compared Idylla™ results against available results from routine diagnostic testing in those sites. MSI mutations detected with the Idylla™ MSI Assay were equally distributed over the seven biomarkers, and 84.48% of the MSI-high samples had ≥ 5 mutated biomarkers, while 98.25% of the microsatellite-stable samples had zero mutated biomarkers. The concordance level between the Idylla™ MSI Assay and immunohistochemistry was 96.39% (988/1025); 17/37 discordant samples were found to be concordant when a third method was used. Compared with routine molecular methods, the concordance level was 98.01% (789/805); third-method analysis found concordance for 8/16 discordant samples. The failure rate of the Idylla™ MSI Assay (0.23%; 3/1301) was lower than that of referenced immunohistochemistry (4.37%; 47/1075) or molecular assays (0.86%; 7/812). In conclusion, lower failure rates and high concordance levels were found between the Idylla™ MSI Assay and routine tests.